Unresectable Angiosarcoma
1 clinical trials · Condition
◉ Watch Unresectable Angiosarcoma
| Record | Firm | Date |
|---|---|---|
| A Phase II Study by Using CICS-1 and SPM-011 Commissioned by CICS and STELLA PHARMA (NCT05601232) | Stella Pharma Corporation | 2022-11-01 |
Track Unresectable Angiosarcoma automatically
Every clearance here is in the API, with alerts when new ones post.